A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Pediatric 6 to 11 Years Old Study)
Latest Information Update: 21 Jun 2023
Price :
$35 *
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms PROMISE Pediatric
- 21 Jun 2023 New trial record
- 09 May 2023 Preliminary results (n=70) assessing fecal microbiota changes in cystic fibrosis children treated with Elexacaftor/Tezacaftor/Ivacaftor, presented at the Digestive Disease Week 2023.